AKST/GRF6019 (formerly known as ALK6019 and GRF6019) is a proprietary human plasma fraction that has been shown to enhance neurogenesis and improve learning and memory in animals, and which has a number of medical and practical advantages over whole plasma. ALK6019 is a highly standardized product produced under rigorous GMP conditions that is stable and can be stored at room temperature. The product candidate is depleted of immunoglobulins, eliminating the need for typing and cross-matching to blood types prior to administration, and depleted of clotting factors for potentially enhanced patient safety. AKST/GRF6019 is being manufactured by Grifols, one of the world’s largest producers of FDA approved blood and plasma derived products.